Please login to the form below

Not currently logged in


This page shows the latest PE news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

BMS and Pfizer’s drug is also used to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip or knee replacement surgery, as a treatment ... of DVT and PE and for the reduction in the risk of recurrent DVT and

Latest news

More from news
Approximately 2 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Earlier in the month the private equity (PE) firm Cinven offered 56 a share to acquire Stada but this has been topped by a binding offer from another PE company, Advent ... A third suitor is believed to be another PE firm, Bain Capital.

  • Pharma deals during November 2014 Pharma deals during November 2014

    It's understood that a number of PE firms are set to acquire the diabetes portfolio, which includes Contour (the blood glucose meter) for $2.5bn.

  • Pharma deals during October 2013 Pharma deals during October 2013

    Overall there was a somewhat eclectic mix of companies featuring in the deals reported and interestingly private equity (PE) companies were involved in several of the transactions. ... The other major deal featuring PE is the acquisition of Acino by

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    2012. Rivaroxaban is also awaiting US approval for the treatment of VTE or PE, and for long-term prevention of recurrent VTE.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...